ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23%
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ESSA Pharma Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Total Liabilities & Equity
$128.1m
CAGR 3-Years
-14%
CAGR 5-Years
19%
CAGR 10-Years
41%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Total Liabilities & Equity
CA$20m
CAGR 3-Years
183%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Total Liabilities & Equity
$69.7m
CAGR 3-Years
-18%
CAGR 5-Years
-8%
CAGR 10-Years
9%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Liabilities & Equity
$549.4m
CAGR 3-Years
15%
CAGR 5-Years
30%
CAGR 10-Years
26%
Covalon Technologies Ltd
XTSX:COV
Total Liabilities & Equity
CA$26.5m
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
11%
Spectral Medical Inc
TSX:EDT
Total Liabilities & Equity
CA$8.2m
CAGR 3-Years
-16%
CAGR 5-Years
10%
CAGR 10-Years
-5%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Total Liabilities & Equity?
Total Liabilities & Equity
128.1m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Total Liabilities & Equity amounts to 128.1m USD.

What is ESSA Pharma Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
41%

Over the last year, the Total Liabilities & Equity growth was -14%. The average annual Total Liabilities & Equity growth rates for ESSA Pharma Inc have been -14% over the past three years , 19% over the past five years , and 41% over the past ten years .

Back to Top